Literature DB >> 11388756

Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel.

R A Heim1, E A Sugarman, B A Allitto.   

Abstract

PURPOSE: To determine the comparative frequency of 93 CFTR mutations in U.S. individuals with a clinical diagnosis of cystic fibrosis (CF).
METHODS: A total of 5,840 CF chromosomes from Caucasians, Ashkenazi Jews, Hispanics, African Americans, Native Americans, Asians, and individuals of mixed race were analyzed using a pooled ASO hybridization strategy.
RESULTS: Sixty-four mutations provided a sensitivity of 70% to 95% in all ethnic groups except Asians, and at least 81% when the U.S. population was considered as a whole.
CONCLUSIONS: For population-based carrier screening for CF in the heterogeneous U.S. population, which is characterized by increasing admixture, a pan-ethnic mutation panel of 50 to 70 CFTR mutations may provide a practical test that maximizes sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388756     DOI: 10.1097/00125817-200105000-00004

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  14 in total

1.  Newborn screening for cystic fibrosis in Alberta: Two years of experience.

Authors:  Margaret Lilley; Susan Christian; Stacey Hume; Patrick Scott; Mark Montgomery; Lisa Semple; Peter Zuberbuhler; Joan Tabak; Fiona Bamforth; Martin J Somerville
Journal:  Paediatr Child Health       Date:  2010-11       Impact factor: 2.253

2.  The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model.

Authors:  Daniel H Farkas; Nicholas E Miltgen; Jay Stoerker; Dirk van den Boom; W Edward Highsmith; Lesley Cagasan; Ron McCullough; Reinhold Mueller; Lin Tang; John Tynan; Courtney Tate; Allan Bombard
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

3.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

4.  A comparative study of five technologically diverse CFTR testing platforms.

Authors:  Monique A Johnson; Marvin J Yoshitomi; C Sue Richards
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

5.  Development of genomic reference materials for cystic fibrosis genetic testing.

Authors:  Victoria M Pratt; Michele Caggana; Christina Bridges; Arlene M Buller; Lisa DiAntonio; W Edward Highsmith; Leonard M Holtegaard; Kasinathan Muralidharan; Elizabeth M Rohlfs; Jack Tarleton; Lorraine Toji; Shannon D Barker; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-04-09       Impact factor: 5.568

6.  Cystic fibrosis testing comes of age.

Authors:  Wayne W Grody
Journal:  J Mol Diagn       Date:  2009-04-09       Impact factor: 5.568

7.  Cystic fibrosis with homozygous R553X mutation in a Taiwanese child.

Authors:  Hui-Ju Chen; Shuan-Pei Lin; Hung-Chang Lee; Chih-Ping Chen; Nan-Chang Chiu; Han-Yang Hung; Schu-Rern Chern; Chih-Kuang Chuang
Journal:  J Hum Genet       Date:  2005-11-10       Impact factor: 3.172

8.  Changing incidence of cystic fibrosis in Wisconsin, USA.

Authors:  Katelyn Parker-McGill; Melodee Nugent; Rachel Bersie; Gary Hoffman; Michael Rock; Mei Baker; Philip M Farrell; Pippa Simpson; Hara Levy
Journal:  Pediatr Pulmonol       Date:  2015-08-10

9.  Carrier screening by next-generation sequencing: health benefits and cost effectiveness.

Authors:  Mohammad Azimi; Kyle Schmaus; Valerie Greger; Dana Neitzel; Robert Rochelle; Tuan Dinh
Journal:  Mol Genet Genomic Med       Date:  2016-01-29       Impact factor: 2.183

Review 10.  Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Authors:  Kamini Jain; Claire Wainwright; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.